ライフサイエンスコーパス: i.d.

1 sing Ascentis Express C18 column (50mmx2.1mm i.d.) packed with 2mum porous shell particles.

2 umn used was an XBridge C18 column (50x2.1mm i.d., 2.5microm particle size), and separation was perfo

3 A fused-core Kinetex C18 column (50x2.1mm i.d.; 2.6mum) was used for the analysis.

4 e was packed into a glass column (1.8 x 0.5 (i.d.) cm) and used in on-line chromatographic system.

5 e was packed into a glass column (1.8 x 0.5 (i.d.) cm) and used in the on-line chromatographic determ

6 After i.d. injection, these mice reliably develop skin graft-v

7 hibited significantly increased firing after i.d. SLIGRL-NH(2) for 9 min, to partial (25%) tachyphyla

8 m the skin to lymph nodes was observed after i.d., but not after s.c., inoculations, we used the latt

9 cterial dose influenced mouse survival after i.d. but not s.c. inoculation.

10 After an i.d. challenge, 15 of 16 mice who were inoculated with p

11 studied using a separation capillary with an i.d. of 25 microns.

12 dministration of plasmid DNA by the i.m. and i.d. routes.

13 nce oligodeoxynucleotide conjugate, i.n. and i.d. IT delivery were similarly effective in modulating

14 Peritoneal and i.d. tumor models are suitable for studying hypoxia in m

15 ypoxia in disseminated peritoneal tumors and i.d. tumors were similar.

16 Oral administration b.i.d. of R115777 to nude mice bearing s.c. tumors at dose

17 asing doses of morphine (5-25 mg/kg, s.c., b.i.d.) and then maintained at 25 mg/kg (b.i.d.) for 4-7 d

18 g SCH66336 doses given orally twice a day (b.i.d.) for 7 days out of every 3 weeks.

19 =2 hours before surgery, then twice a day (b.i.d.) until hospital discharge or for up to 7 days.

20 ce daily (q.d.), timolol 0.5% twice a day (b.i.d.), and (ROCKET-2 only) netarsudil 0.02% b.i.d.

21 doses of 237 micromol/kg/day twice a day (b.i.d.), there was serious proximal tubule damage versus 4

22 4 groups: posaconazole 400 mg twice a day (b.i.d.); benznidazole 200 mg + placebo b.i.d.; benznidazol

23 -treated (5 days at 10 mg kg-1 bis in die (b.i.d.)) rats decreased renal blood flow by 46 and 29 % (b

24 r CEP-5214 to CD-1 mice at 23.8 mg/kg/dose b.i.d. resulted in a reversible inhibition of VEGF-R2/FLK-

25 .o. of CEP-7055 at 2.57 to 23.8 mg/kg/dose b.i.d. resulted in dose-related reductions in neovasculari

26 P-7055 at doses of 11.9 to 23.8 mg/kg/dose b.i.d. resulted in significant inhibition (50-90% maximum

27 er, we show that rifampin (75 or 100 mg/kg b.i.d. for 3 d, intraperitoneal) suppressed allodynia indu

28 , b.i.d.) and then maintained at 25 mg/kg (b.i.d.) for 4-7 days.

29 r providing >99% inhibition at 12.5 mg/kg (b.i.d., orally) in the Leishmania infantum hamster model.

30 odels of contact hypersensitivity (1 mg/kg b.i.d.) and house dust (20 mg/kg q.d.) when dosed orally.

31 crease in weight gain observed at 36 mg/kg b.i.d.).

32 nserin (3 mg/kg), or haloperidol (1 mg/kg) b.i.d. 30 min before PCP (2 mg/kg, b.i.d.) for 7 days (day

33 mg/kg) b.i.d. 30 min before PCP (2 mg/kg, b.i.d.) for 7 days (day1-7), followed by a 7-day washout (

34 toneal injection of TRK820 (0.1-10 mug/kg, b.i.d.) significantly inhibited tumor growth by suppressin

35 mice when administered orally at 25 mg/kg, b.i.d., for 4 days.

36 closporine microemulsion (Neoral) 60 mg/kg/b.i.d. on days +1 to +3 with dose adjusted by blood levels

37 bleeding was lower with dabigatran 110 mg b.i.d. (aHR: 0.60, 95% CI: 0.37 to 0.93) compared with war

38 or placebo (n=2), the second cohort 40 mg b.i.d. (n=6) or placebo (n=2), and the third cohort 40 mg

39 0 mg + placebo b.i.d.; benznidazole 200 mg b.i.d. + posaconazole 400 mg b.i.d.; or placebo 10 mg b.i.

40 on PPI and the dose was increased to 40 mg b.i.d. 31 consecutive patients with typical reflux symptom

41 in groups A and C; 4 to 6 ng/mL and 500 mg b.i.d. in group B.

42 MMF dosing were 5 to 7 ng/mL and 1,000 mg b.i.d. in groups A and C; 4 to 6 ng/mL and 500 mg b.i.d. i

43 The target asenapine dosage was 10 mg b.i.d. in the open-label period but could be titrated down

44 One group received sodium naproxen 550 mg b.i.d. plus placebo for 7 days, while the other group rece

45 ther group received sodium naproxen 550 mg b.i.d. plus rebamipide 100 mg b.i.d.

46 saconazole 400 mg b.i.d.; or placebo 10 mg b.i.d. T. cruzi deoxyribonucleic acid was detected by RT-P

47 diabetic subjects taking metformin 850 mg b.i.d. versus placebo.

48 sustained-release bupropion (up to 200 mg b.i.d.) (N=21) to patients receiving placebo (N=19).

49 ither placebo capsules + AFS or LDD (20 mg b.i.d.) + AFS.

50 fen (LDF) alone, 50 mg q.d.; 2) SDD (20 mg b.i.d.) alone; or 3) a combination of SDD plus LDF (combin

51 , followed by maintenance on placebo (0 mg b.i.d.) and active ibudilast (50 mg b.i.d.).

52 or future testing on this schedule (350 mg b.i.d.) but also provides the first evidence of successful

53 However, Org 26576 (100-300 mg b.i.d.) did not confirm these results.

54 ces: sequence A (n = 15) Org 26576 (100 mg b.i.d.) for 3 weeks, followed by a 2-week placebo crossove

55 = 18) Org 26576 flexible dose (100-300 mg b.i.d.) for 3 weeks, then 5 weeks placebo; sequence D (n =

56 l human laboratory efficacy of IBUD (50 mg b.i.d.) on primary measures of subjective response to alco

57 ee months of rosiglitazone treatment (4 mg b.i.d.) on whole-body insulin sensitivity and in vivo peri

58 icotinic receptor PAM JNJ-39393406 (100 mg b.i.d.) or placebo (double-blind, counter-balanced).

59 s treated with either vildaglipitin (50 mg b.i.d.) or placebo for 10 days using a double-blind, place

60 Org 26576 (100 mg b.i.d.) was superior to placebo in treating symptoms of ad

61 (0 mg b.i.d.) and active ibudilast (50 mg b.i.d.).

62 followed by 3 weeks Org 26576 (100-300 mg b.i.d.).

63 cebo followed by 3 weeks Org 26576 (100 mg b.i.d.); sequence C (n = 18) Org 26576 flexible dose (100-

64 ., aHR: 0.24, 95% CI: 0.08 to 0.56; 150 mg b.i.d., aHR: 0.08, 95% CI: 0.01 to 0.40).

65 as seen with both dabigatran doses (110 mg b.i.d., aHR: 0.24, 95% CI: 0.08 to 0.56; 150 mg b.i.d., aH

66 s lower with both dabigatran doses (110 mg b.i.d., aHR: 0.30, 95% CI: 0.18 to 0.49; 150 mg b.i.d., aH

67 ., aHR: 0.30, 95% CI: 0.18 to 0.49; 150 mg b.i.d., aHR: 0.40, 95% CI: 0.21 to 0.70).

68 idence interval [CI]: 0.65 to 0.95; 150 mg b.i.d., aHR: 0.57, 95% CI: 0.40 to 0.80), when compared wi

69 y lower with both dabigatran doses (110 mg b.i.d., propensity-match group stratified hazard ratio [aH

70 dazole 200 mg b.i.d. + posaconazole 400 mg b.i.d.; or placebo 10 mg b.i.d. T. cruzi deoxyribonucleic

71 d., 59% (149/253, ROCKET-2) for netarsudil b.i.d., and 8% (17/208, ROCKET-1) to 11% (27/251, ROCKET-2

72 24 h after induction of MR (60 mg/kg p.o. b.i.d.) and continued for three months.

73 o. t.i.d.; n=19) or acyclovir (200 mg p.o. b.i.d.; n=23) was begun at transplantation and continued f

74 Two doses of VEGFR2-TKI (25 mg/kg, p.o., b.i.d.) resulted in a decrease of V(b) to 1.3 +/- 0.3%.

75 P.o. administration (q.d. or b.i.d.) of CP-724,714 inhibits the growth of erbB2-overexp

76 ment with ganciclovir (GCV), 10 mg/kg i.p. b.i.d. for 6 days.

77 d with 40 mg pantoprazole (PPI) or placebo b.i.d. was performed.

78 ay (b.i.d.); benznidazole 200 mg + placebo b.i.d.; benznidazole 200 mg b.i.d. + posaconazole 400 mg b

79 rteether as controls, were administered po b.i.d. (128 mg/kg/day) to P. berghei-infected mice on days

80 Immunostimulation by i.d. LT(G33D) is explained by its ability to induce migr

81 Fused silica capillaries (i.d. 50 microm, o.d. 360 microm) are employed as the dig

82 ized on the inner wall of a glass capillary (i.d. 0.8 mm, length = 5-15 cm).

83 d that lowest flow rates and smallest column i.d. gave the highest relative signal.

84 mpounds are observed to increase with column i.d., suggesting an increase in packing density.

85 renteral vaccines in general and for current i.d. vaccine development in particular.

86 f a ring electrode ion guide with decreasing i.d. and with a superimposed dc potential gradient along

87 cale containers in which the inner diameter (i.d.) and surface chemistry can be systematically and in

88 specifically a 20 m, 100 mum inner diameter (i.d.) capillary column with a 0.4 mum film thickness to

89 Using 1.5 microm inner diameter (i.d.) capillary columns, hydrodynamically injecting femt

90 00 psi) for packed 10-microm-inner diameter (i.d.) columns.

91 2 to 2 microL/min and column inner diameter (i.d.) from 25 to 75 microm on the relative signal obtain

92 OP) capillary column with an inner diameter (i.d.) of 28 mum and using an on-capillary admittance det

93 interface featuring a large inner diameter (i.d.) separation capillary, and a detachable small i.d.

94 he tumor corresponds to 22.2% injected dose (i.d.) per g of tissue, a value analogous to the most pro

95 ditions of natural route of challenge (i.e., i.d. inoculation), the immune response has the capacity

96 Employing i.d. inoculation to model sand fly transmission of paras

97 s were the dominant infected cells following i.d., but not s.c. or i.p., inoculation.

98 d acute cellular responses in mice following i.d. inoculation of the ear, subcutaneous (s.c.) inocula

99 uch-evoked scratching was observed following i.d. 5-HT (5-hydroxytryptamine), a protease-activated re

100 IgG-secreting cells were produced following i.d. immunization.

101 Ag-specific Abs compared with one of six for i.d. and two of six for i.l. routes.

102 were pretreated i.v. with human IgG (hIgG), i.d. injections of SpA induced an inflammatory response

103 r the independent identically distributed (i.i.d.) background model.

104 f independent and identically distributed (i.i.d.) draws does not come from a specified probability d

105 f independent and identically distributed (i.i.d.) random variables, i.e., a Bernoulli sequence.

106 um of independent identically distributed (i.i.d.) random variables.

107 s independent and identically distributed (i.i.d.) samples from the multivariate normal distribution.

108 distribution function for the given set of i.i.d. draws.

109 adhesion events revealed violation of the i.i.d. assumption, depending on the receptor-ligand system

110 y marginalizing the 4( t ) patterns of the i.i.d. model to observed and expected parsimony counts, th

111 Rabbits immunized i.d. with 10 mug of rPA displayed 100% protection from a

112 they traverse fused-silica tubing ranging in i.d. from 25 to 75 microm.

113 etween the FAIMS exit and a capillary inlet (i.d. = 0.5 mm).

114 Intradermal (i.d.) immunization is a promising route of vaccine admin

115 Intradermal (i.d.) immunization of mice with recombinant PspA in comb

116 Intradermal (i.d.) infection with IOE established mild, self-limited

117 Intradermal (i.d.) injection of the PAR-2 agonist SLIGRL-NH(2) in the

118 Following acute intradermal (i.d.) injection of histamine in the rostral back, mechan

119 tive immunity in macaques after intradermal (i.d.) or intramuscular (i.m.) delivery of 0.5 to 1 mg of

120 We developed an intradermal (i.d.) injection model in which CD8+ T (OT-I) cells that

121 termine its efficacy against an intradermal (i.d.) or intranasal (i.n.) challenge with vaccinia virus

122 from intraperitoneal (i.p.) and intradermal (i.d.) challenge by L. interrogans serovar Copenhageni st

123 eminated peritoneal disease and intradermal (i.d.) growing tumors.

124 ared were intranasal (i.n.) and intradermal (i.d.) inoculation of the Francisella tularensis live vac

125 of vaccine by microneedle-based intradermal (i.d.) delivery or intramuscular (i.m.) injection using c

126 luated single versus concurrent intradermal (i.d.) and intramuscular (i.m.) vaccinations as a DNA-pri

127 Dorsal intradermal (i.d.) administration of AYP elicited intense scratching

128 transmitted in nature following intradermal (i.d.) deposition of parasites by the bite of an infected

129 ous report where we implemented intradermal (i.d.) inoculations to study bacterial dissemination duri

130 The intradermal (i.d.) injection of LPS into gp49B1-null (gp49B-/-) but n

131 by the intranasal (i.n.) vs the intradermal (i.d.) route.

132 ized with Ag-pulsed DC by i.v., intradermal (i.d.), or intralymphatic (i.l.) injection.

133 of IpaB and IpaD administered intradermally (i.d.) with a double-mutant of the Escherichia coli heat-

134 th 1.2 mg of DNA administered intradermally (i.d.; group A), 1.2 mg of DNA administered intramuscular

135 er 1800 micro g both i.m. and intradermally (i.d.); 9 of 12 patients had humoral (n = 6) and/or T-cel

136 t-knockout (KO) mice infected intradermally (i.d.) or intranasally (i.n.) with LVS succumbed to infec

137 s jet injection [i.m. or i.m./intradermally (i.d.)] in 14 volunteers.

138 ed with LVS DeltacapB i.n. or intradermally (i.d.) developed humoral and cellular immune responses co

139 , which were administered SpA intradermally (i.d.), do not develop a cutaneous inflammatory response.

140 to mice infected intraperitoneally with IOE, i.d. infection stimulated a stronger protective type-1 c

141 olithic capillary columns (25 cm x 10 microm i.d.) with integrated nanoESI emitters have been develop

142 and Rhodamine 6G, are obtained in 100 microm i.d. fused-silica capillaries under CE conditions using

143 r that moves through a capillary (100 microm i.d.) at a speed approximately 20 cm/s, under laminar fl

144 icides using capillary columns of 100-microm i.d. packed with a 5-microm octadecyl silica (ODS) stati

145 ylate) monoliths were prepared in 150 microm i.d. capillaries using novel binary porogenic solvents c

146 into fused-silica capillaries (50-150-microm i.d.) to form affinity chromatography columns.

147 ormance of high-efficiency 70 cm x 20 microm i.d. silica-based monolithic capillary LC columns.

148 microm i.d. x 360 microm o.d. and 20 microm i.d. x 360 microm o.d. capillaries within the flow rate

149 with a small dispensing aperture (20-microm i.d.) by constriction of a cylindrical piezoelectric ele

150 were achieved in CEC on a 64 cm x 25 microm i.d. sol-gel ODS open tubular column.

151 when passed through tubing with a 25-microm i.d. and a length of 100 cm.

152 Fused-silica capillary LC columns (25-microm i.d.) with 3-microm-i.d. integrated electrospray emitter

153 s (bPAECs) in microbore tubing of 250-microm i.d. are described.

154 ry, to 5-10 microm, which for a 20-30 microm i.d. capillary results in stable electrospray at approxi

155 ly useful for interfacing narrow (<30 microm i.d.) capillaries and low flow rates (<100 nL/min).

156 ht parallel channels (10 mm long, 360 microm i.d.) connected via external fused-silica capillaries.

157 thick tissue cross section into a 50 microm i.d. capillary where the tissue was solubilized with a s

158 column) were achieved on a 50 cm x 50 microm i.d. column using polycyclic aromatic hydrocarbons and a

159 pray and excellent performance for 50 microm i.d. x 360 microm o.d. and 20 microm i.d. x 360 microm o

160 The system uses 50 microm i.d. x 40-200 cm fused-silica capillaries packed with 1.

161 analysis times when capillaries of 50-microm i.d. or smaller are used.

162 spectrometry (LC-MS/MS) analyses, 75 microm i.d. x 14 cm capillary columns were interfaced with a co

163 rradiated at 365 nm for 5 min in a 75-microm i.d. capillary to prepare a porous monolithic sol-gel co

164 30-cm-long fused-silica capillary (75-microm i.d.) with dopamine, catechol, and ascorbic acid serving

165 monoliths were synthesized inside 75-microm i.d., UV-transparent fused-silica capillaries by photopo

166 SiHa cells, using a typical 15 cmx75 microm i.d. packed capillary column.

167 rodialysis membranes (3 mm lengthx200 microm i.d.) have been used to extract volatile analytes from a

168 e complexes are flowed through a 150-microm (i.d.) capillary cell and detected using a low-power He-N

169 A 50 microm (i.d.) x 38 cm (effective length) fused silica capillary

170 on rat mesenteric lymphatics (90-220 microm, i.d.) using servo-controlled wire- and pressure-myograph

171 (styrene-divinylbenzene) (PS-DVB), 10-microm-i.d. porous layer open tubular (PLOT) capillary columns

172 s have been determined for 25- and 10-microm-i.d. silica capillaries.

173 The reactor has been used with 100-microm-i.d. columns with insignificant effects (i.e., <3%) on p

174 producibly resolved by CIEF using 100-microm-i.d. fused-silica capillaries coated with hydroxypropyl

175 retical plates for 75-microm- and 100-microm-i.d. separation capillaries are 1.6 x 10(5) and 2.5 x 10

176 capacities of approximately 10(3)) 15-microm-i.d. capillary liquid chromatography separations (i.e.,

177 y125-cm) and narrow (approximately 15-microm-i.d.) capillary, the four major proteins of the RBC, whi

178 ysis of a standard peptide using a 20-microm-i.d. capillary.

179 A single, 7-cm, 20-microm-i.d. fused-silica capillary (total volume, 70 nL), with

180 This work explores the use of 20-microm-i.d. polymeric polystyrene-divinylbenzene monolithic nan

181 ith an underivatized, 130-cm-long, 20-microm-i.d., 150-microm-o.d. fused-silica capillary and by moni

182 tomole levels using a 130-cm-long, 20-microm-i.d., 150-microm-o.d. underivatized fused-silica capilla

183 In a 25-microm-i.d. tube, the amount of ATP released from the RBCs incr

184 ry LC columns (25-microm i.d.) with 3-microm-i.d. integrated electrospray emitters interfaced to a qu

185 cles were obtained and packed into 30-microm-i.d. fused-silica capillary columns up to 50 cm in lengt

186 A single 30-microm-i.d. fused-silica capillary was used both as the reactio

187 -microm porous C18 particle-packed 50-microm-i.d. capillaries were used to speed the RPLC separations

188 capillary lengths (180 cm) with a 50-microm-i.d. capillary (24.5 cm effective capillary length), tot

189 rylate) monolith prepared within a 50-microm-i.d. capillary.

190 ith matrix flowing from a separate 50-microm-i.d. capillary.

191 of proteins was carried out using 50-microm-i.d. fused-silica capillaries packed with 5-microm silic

192 The RPLC separations used 50-microm-i.d. fused-silica capillaries packed with submicrometer-

193 ample is deposited directly from a 50-microm-i.d. separation capillary onto the 19-mm ball that is ro

194 ormed on a quadrupole ion trap, a 500-microm-i.d. waveguide was used as a medium to transmit IR radia

195 a MPN film was obtained in a 2-m, 530-microm-i.d. deactivated silica capillary using gravity to force

196 oteolytic peptides for 14.9- and 29.7-microm-i.d. packed capillaries, respectively), the nanoLC/nanoE

197 nd again pressure on 25-, 50-, and 75-microm-i.d. capillaries are shown.

198 monolith was synthesized inside a 75-microm-i.d. capillary by photoinitiated copolymerization with w

199 sin I, the carbon fiber emitter in 75-microm-i.d. fused-silica tubing was shown to give ion current c

200 of up to 20-fold improvement over 75-microm-i.d. nanocolumns.

201 latinum wire was inserted into the 75-microm-i.d. separation capillary.

202 trode with a separation capillary (30-micron i.d., 75-cm length).

203 ng a 60-cm fused-silica capillary (50-micron i.d., 35-cm effective length), six of which were detecte

204 ser is focused at the outlet of a 0.6-micron i.d. capillary, producing pulse intensities of approxima

205 its for these toxins separated in 2.1-micron-i.d. capillaries range from 4.4 zmol (approximately 2700

206 The mixture was loaded into 150-micron-i.d. fused-silica capillary tubing with a pulled 5-10-mi

207 Larger (16-micron-i.d.) separation capillaries provide concentration detec

208 in a single file confined within a 20-micron-i.d. capillary.

209 were injected onto a 4-cm-long by 50-micron-i.d. RPLC column.

210 ersed-phase separation of peptides on a 1 mm i.d. column operating at flow rate of 50 microL/min.

211 ed in series with a diol column, both 2.1 mm i.d. x 150 mm long, packed with 5-mum spherical silica-b

212 s method uses an immunoaffinity column (1 mm i.d. x 20 mm) for on-line sample cleanup and enrichment,

213 us, we constructed a tubular structure (1 mm i.d.) from aligned human mesenchymal cell sheets (hMSC)

214 A glass capillary (1.1 mm i.d.) packed with 3.4 mg of Carbopack X and 1.2 mg of Ca

215 (BEH) C18 reversed-phase column (50 x 2.1 mm i.d., 1.7-microm particle size) with gradient elution at

216 ersil C8 HyPurity Advance column (100x2.1 mm i.d., 3 microm) was used with a flow rate of 0.3 ml/min)

217 chieved on a Waters X-Terra C18 (50 x 2.1 mm i.d., 3.5 microm) analytical column with acetonitrile/wa

218 per, we compare a narrow-bore column (2.1-mm i.d.) to a conventional-bore column (4.6 mm i.d.) at ele

219 ocities by using narrow-bore columns (2.1-mm i.d.).

220 The modulator tube is 0.18 mm i.d. x 8 cm in length.

221 The capillary column ensemble (0.18-mm i.d. x 0.18-microm film thickness) consists of a 7.0-m l

222 ng, a 3-micron C18 analytical column (3.2 mm i.d. x 100 mm) for separation, and a membrane introducti

223 chment, a 5-micron C18 trapping column (2 mm i.d. x 20 mm) for analyte focusing, a 3-micron C18 analy

224 ogenic water trap with narrow-bore (<0.20 mm i.d.) transfer lines, and a narrow i.d. open split to th

225 tly anchored to the inner walls of a 0.25 mm i.d. fused silica capillary to produce a sol-gel germani

226 al plates/m was obtained on a 10 m x 0.25 mm i.d. fused-silica capillary column.

227 was found that with a 6-meter-long, 0.25-mm i.d. column programmed at a rate of 600 degrees C/min, a

228 capsule and a progesterone capsule (3.35 mm i.d., 4.65 mm o.d., 3.0 cm long) together at 09.00 h on

229 low-field (47.5 mT) preclinical scale (38 mm i.d.) 2D magnetic resonance imaging (MRI).

230 When a 4.5 mm i.d. x 0.95 mm monolith disk containing anti-FITC antibo

231 With the use of packed microcolumns (<0.5 mm i.d.), essentially instantaneous heat transfer from the

232 ts each received a silastic capsule (1.57 mm i.d., 3.18 mm o.d., 1.5 cm long) containing estradiol-17

233 a progesterone implant (crystalline, 1.57 mm i.d., 3.18 mm o.d., 1.5 cm long).

234 The 20 muL min(-1) flow rate of 6 mm i.d. pumps with Nafion coated electrodes operate daily f

235 i.d.) to a conventional-bore column (4.6 mm i.d.) at elevated temperatures under conditions where th

236 low rate of 15 mL/min with a 5 cm by 4.6 mm (i.d.) column packed with 3 microns polystyrene-coated zi

237 ed columns (lengths 30, 50, 100, and 150 mm, i.d., 1 and 2.1 mm, all packed with Acquity UPLC, BEH-C

238 fraction was extracted in 180 ms by a 2.1-mm-i.d. sandwich microcolumn that contained a 1.1-mm layer

239 ure moves between three heat zones in a 1-mm-i.d., oil-filled capillary using a multielement scattere

240 A 14-m-long, 0.18-mm-i.d. column ensemble consisting of 7.0-m lengths of a tr

241 y microbore and minibore HPLC (packed 1-2-mm-i.d. columns).

242 sure air as carrier gas, a 6-m-long, 0.25-mm-i.d. capillary column can generate approximately 12,500

243 tandem ensemble of two 4.5-m-long x 0.25-mm-i.d. capillary columns with the first using a 0.50-micro

244 ation is performed with a 15-m-long, 0.25-mm-i.d. capillary using a 0.5-microm-thick film of nonpolar

245 A 12-m-long, 0.25-mm-i.d. tandem column ensemble consisting of 4.5-m dimethyl

246 d-dimension column was a 0.5 m long, 100 mum i.d. capillary with a poly(ethylene glycol) phase.

247 nolithic capillary column (16.5 cm x 150 mum i.d.) synthesized from poly(ethylene glycol) diacrylate.

248 s of the RP analytical column down to 25 mum i.d. for an additional 2- to 3-fold improvement in perfo

249 to 7,000,000 theoretical plates in a 25 mum i.d. fused silica capillary.

250 GC x GC separations was a 6 m long, 250 mum i.d. capillary with a PDMS stationary phase, and the sec

251 t test mixture separated on a 30 m x 250 mum i.d. RTX-5 column with a LECO Pegasus III TOFMS.

252 fiber (50 mum of wall-thickness and 280 mum i.d.), this setup allowed for a continual renewal of the

253 It is demonstrated that 5 mum i.d. capillaries can be coated with mesoporous silica la

254 lts were obtained with a capillary of 50 mum i.d. x 50 cm effective length, sodium tetraborate 40 mM

255 te] monoliths were synthesized inside 75 mum i.d. capillaries by one-step UV-initiated copolymerizati

256 e synthesize polymer monoliths inside 75 mum i.d. capillaries, use these monoliths to assemble miniat

257 Each monolith in a 75 mum i.d. capillary is equivalent to several thousands of ope

258 ction windows was used with a 95 cm x100 mum i.d. capillary.

259 tic flow through an 11 cm (length) x 50 mum (i.d.) sampling capillary is introduced to a simple micro

260 and ethylene dimethacrylate inside a 100-mum-i.d. capillary.

261 (<0.20 mm i.d.) transfer lines, and a narrow i.d. open split to the IRMS directly inserted into the c

262 pA in combination with LT-IIb(T13I), a novel i.d. adjuvant of the type II heat-labile enterotoxin fam

263 These results demonstrate the potential of i.d. vaccination with IpaB and IpaD to prevent Shigella

264 Immune T lymphocytes from the spleens of i.d. LVS-vaccinated WT or KO mice controlled intracellul

265 -inoculated mouse lung tissues from those of i.d.-inoculated and control mouse lung tissues.

266 y, mice immunized with LVS DeltacapB i.n. or i.d. and then challenged 6 weeks later by aerosol with 1

267 leptospiral challenge by either the i.p. or i.d. route.

268 3 months of either oral acyclovir (800 mg q.i.d.) or oral ganciclovir (1000 mg t.i.d.).

269 IO mice, administration of MTII 100 microg q.i.d. i.p. markedly suppressed feeding during the first 4

270 MTII administration (100 microg q.i.d. i.p.) for 24 h results in similar weight loss but a

271 indicate that the more biologically relevant i.d. model of bubonic plague differs significantly from

272 ricted rat mesenteric small arteries (RMSAs, i.d. 200-300 microm) was studied using small vessel myog

273 age versus 474 micromol/kg/day once daily (s.i.d.).

274 cal Shwartzman reaction (LSR) after a single i.d. injection of LPS, whereas in the classic LSR, a sec

275 separation capillary, and a detachable small i.d. porous electrospray ionization (ESI) emitter was de

276 ical calculations indicate that even smaller i.d. columns can be used with little effect on chromatog

277 Suitable i.d. adjuvants are important to increase vaccine efficac

278 adult dose of 4PBA, 19 grams p.o. divided t.i.d., given for 1 wk.

279 received oral ganciclovir for 6 weeks (2 g t.i.d. for 2 weeks, then 1 g t.i.d. for 4 weeks), and the

280 6 weeks (2 g t.i.d. for 2 weeks, then 1 g t.i.d. for 4 weeks), and the control group received i.v. g

281 placebo (n=2), and the third cohort 40 mg t.i.d. (n=6) or placebo (n=2).

282 on one of two regimes of pindolol (2.5 mg t.i.d. and 5.0 mg t.i.d.) with PET and [11C]WAY-100635.

283 3) SRP plus metronidazole capsule (250 mg t.i.d. for one week).

284 The 5-mg t.i.d. regime achieved a modest (19%) but significant occu

285 e vast majority of clinical trials (2.5 mg t.i.d.) did not achieve a significant occupancy.

286 omized to receive baclofen (60 mg/d; 20 mg t.i.d.) or placebo.

287 imes of pindolol (2.5 mg t.i.d. and 5.0 mg t.i.d.) with PET and [11C]WAY-100635.

288 00 mg q.i.d.) or oral ganciclovir (1000 mg t.i.d.).

289 glucosamine at standard doses (500 mg p.o. t.i.d.) in lean (n = 20) and obese (n = 20) subjects.

290 Ganciclovir (1000 mg p.o. t.i.d.; n=19) or acyclovir (200 mg p.o. b.i.d.; n=23) was

291 ed to compare addition of 5 mg of pindolol t.i.d. or placebo for 4 weeks to a steady paroxetine dose.

292 hain amino acids (222 mg/kg of body weight t.i.d.) (N=18) and those who received placebo (N=18) in th

293 suggest that i.n. IT is more effective than i.d. IT for the treatment of asthma.

294 We have reported that i.d. injection of plasmids encoding hsp70 and a suicide

295 the magnitude of CD4 T-cell responses in the i.d. group was indistinguishable from those in the other

296 nitude after the DNA vaccinations, while the i.d. group exhibited the responses of the least magnitud

297 cine was administered intranasally, with the i.d. route requiring 25-40 times lower doses.

298 ated twice with 20 mug of DNA plus Vaxfectin i.d., 100 mug of DNA plus Vaxfectin i.d., 100 mug of DNA

299 axfectin i.d., 100 mug of DNA plus Vaxfectin i.d., 100 mug of DNA plus Vaxfectin i.m. or 100 mug of D

300 In these studies, single nanotubes with i.d.'s of either 30 or 170 nm were investigated over a r

301 amma production, however, was seen only with i.d. and i.l. routes of administration, and no IL-4 resp